Securities Class Action Lawsuit Filed Against Hims & Hers Health, Inc.

Strategic Insights -

A securities class action lawsuit has been filed on behalf of investors who purchased Hims & Hers Health, Inc. securities between April 29, 2025, and June 23, 2025. The suit alleges that the company made false and/or misleading statements regarding its promotion and sale of Wegovy, a prescription medication, which led to a decline in stock price.

The lawsuit alleges that Hims & Hers engaged in the deceptive promotion and selling of illegitimate, knockoff versions of Wegovy, which put patient safety at risk. The company's collaboration with Novo Nordisk A/S was subsequently terminated due to these actions. As a result, the price of Hims & Hers stock fell by over 34%.

Investors who purchased Hims & Hers securities during the class period should contact a law firm specializing in securities litigation to discuss potential claims. The lead plaintiff motion deadline is August 25, 2025.

Key Takeaways:

  • The Hims & Hers class action lawsuit alleges that the company engaged in the deceptive promotion and selling of illegitimate, knockoff versions of Wegovy, which put patient safety at risk.
  • The lawsuit further alleges that the company's collaboration with Novo Nordisk A/S was terminated due to these actions, leading to a decline in stock price.
  • Investors who purchased Hims & Hers securities during the class period may be eligible to participate in the lawsuit.
  • The lead plaintiff motion deadline is August 25, 2025.
  • Wolf Haldenstein Adler Freeman & Herz LLP, a law firm with over 125 years of experience in securities litigation, is representing the plaintiffs in this case.

Statistics:

  • The price of Hims & Hers stock fell $18.26 per share, to close at $45.00 per share, a decline of more than 34%.
  • The class period spans from April 29, 2025, to June 23, 2025.
  • The lead plaintiff motion deadline is August 25, 2025.
  • Wolf Haldenstein Adler Freeman & Herz LLP has over 125 years of experience in securities litigation.
  • The firm has a proven track record of protecting the rights of investors.

Sources:

  • Wolf Haldenstein Adler Freeman & Herz LLP
  • PRNewswire
  • Hims & Hers Health, Inc.
  • Novo Nordisk A/S
  • FDA (U.S. Food and Drug Administration)